Kristin Giacoman, RN,BSN,MSN

• Increased organizational efficiency across different Cross-Portfolio Teams by streamlining processes and implementing new systems
• Collaborate with matrix partners (Squad/Network/CMG)
• Led organizational change initiatives, resulting in a more agile and responsive workforce
• Work across payer landscape National/Regional & IDN
• Built Leadership Development program for 1st/2nd line leaders across customer engagement & HBA
• Launch Lead for 2 key launches across Immunology (Xolair) and Neurology (Zunovo)

• Leading a team of 8 MSL's across the West & Central Regions to deliver scientific data to HCPs
• Executing on the Strategic Medical Strategy Cross-portfolio while collaborating across USMA, Marketing & Commercial teams
• Building strong KOL relationships across Ecosystems and removing obstacles for customers to deliver therapy to patients
• Key member of various projects such as Insights Evolution, Community of Practice, Team Portal, Analytics, Personas, g-Mind, AI and Veeva

• Leading an award winning team of 10 Account Managers across the Southwest focusing on Pan-Tumor NTRK Biomarker
• Sales Team focuses on P&T formulary/Pathway > 80% Academic Accounts, Pediatric Hospitals, VA, KP
• Coaching sales team on treatment landscapes across multiple tumor types as well as NGS modalities
• Instrumental in leading across-functional Texas Oncology Taskforce

• 1st and 2nd line leadership for a team of five Regional Managers and 45+ Field Reimbursement Managers, Access/HEOR and Nurse Educators by providing an outstanding customer experience and ensuring alignment between brand strategy and patient satisfaction. Managed >50+.
• Ensuring effective transition during launch of Field Reimbursement Team deployment and HUB, ESPN and SP alignment in Immunology & Neurology launches
• Challenging the status quo to enable change and empowerment
• CEO Culture Award 2019

• Buildout of Launch Partner Team responsible for Onivyde launch for Pancreatic/GIST IV drug
• Instrumental in setting vision and rules of engagement at launch
• Cross-functional tactical roll-out of KOL Ad Boards/Speaker programs and leverage key relationships with GI Oncologists
• Developed Analytics tools to help Medical/Clinical Partner team decipher Health Economics and correlations to key customers
• Strat Plan, Medical Advisory Board and Pathways Committee

• Reporting to SVP Medical for a start-up Cardiac Surgery company with a Class III Med device focusing on the CHF/VAD space with focus on the Cardiac Surgery and Cath-Lab markets
• Managed thru FDA halt of study and later entire program, CEO and board hostile takeover, lost funding and later downsizing
• C-Suite and Director level presentations to show P & L of bringing a CHF/VAD and Research program into their facility,
• Trial initiation, training and pull-through for major Academic Cardiac Surgery programs. 95% SIV success

• Reporting to VP of Sales for a start-up Interventional Oncology company focusing on Liver/m-CRC and Rare GIST cancer
• One of Two initial Directors hired to build-out initial sales force and management of a team of 40 Reps
• Managed acquisition of two business units in Chemo-embolic/Brachytherapy space, Managed 2 launches
• National Payer/IDN/GPO negotiations responsibility
• Distributor buildout and Payor Relationships as well as C-suite for Med Device/Drug Combo product
• Annual sales growth Year One-156% and Year Two-128%, 2013-President's Club Division and top Regions award

• 1st and 2nd line management responsibility for a team of 45+ selling into Cath-Lab. Pacemakers, Heart Valves, closure devices and Ensite Ablation system
• Managed West Field Medical Team (FCE CPIE Division)
• Selected for Management Development Ad Board
• In five years grew business from $25 million to over $145 million in CRM alone
• Corporate Accounts responsibility. President's Club-2006/2008 and Circle of Excellence 2005/2007

• Individual contributor supporting Pacemaker and ICD cases in OR and Cath-Lab. In three years grew territory from $400,000 to $4.8 million. Over 120% to plan growth X 3 Years, Rookie of Year Award 2003

Rare Disease, Orphan Space, GI